Preventing attacks of acute gout when introducing urate-lowering therapy: A systematic literature review

Journal of Rheumatology

Volumn 41, Issue SUPPL. 92, 2014, Pages 42-47

  Seth, Rakhi ^b   Kydd, Alison S R ^c   Falzon, Louise ^d   Bombardier, Claire ^e,f,g   Van Der Heijde, Désirée M ^a   Edwards, Christopher J ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Department of Medicine   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Colchicine; Flare prophylaxis; Gout; Urate lowering therapy

Indexed keywords

URICOSURIC AGENT;

BLOOD; DRUG ADMINISTRATION; GOUT; HUMAN; TIME; TREATMENT OUTCOME;

DRUG ADMINISTRATION SCHEDULE; GOUT; HUMANS; TIME FACTORS; TREATMENT OUTCOME; URICOSURIC AGENTS;

EID: 84906849892     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140461     Document Type: Review

References (18)

1. Sivera F, Andrés M, Carmona L, Kydd AS, Moi J, Seth R, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: Integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Ann Rheum Dis 2014;73:328-35.
2. Yamanaka H, Togashi R, Hakoda M, Terai C, Kashiwazaki S, Dan T, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998;431:13-8. (Pubitemid 28236731)
3. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, Version 5.1.0 [updated March 2011; accessed April 18, 2012]. The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org
4. Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, Dalbeth N, et al. Outcomes domains for studies of acute and chronic gout. J Rheumatol 2009;36:2342-5.
5. Higgins JPT, Altman DG, Sterne JAC, editors. Ch 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, Version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011. Available from www.cochrane-handbook.org
6. Templeton JS. Azapropazone or allopurinol in the treatment of chronic gout and/or hyperuricaemia. A preliminary report. Br J Rheumatol 1984;23:44-51.
7. Daymond TJ, Laws D, Templeton JS. A comparison of azapropazone and allopurinol in the treatment of chronic gout. Br J Clin Pharmacol 1983;15:157.
8. Fraser RC, Davis RH, Walker FS. Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia. J R Coll Gen Pract 1987;37:409-11. (Pubitemid 17124130)
9. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429-32. (Pubitemid 39610535)
10. Paulus HE, Schlosstein LH, Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum 1974;17:609-14.
11. Karimzadeh H, Nazari J, Mottaghi P, Kabiri P. Different duration of colchicine for preventing recurrence of gouty arthritis. J Res Med Sci 2006;11:104-7. (Pubitemid 44348452)
12. Schlesinger N, Mysler E, Lin HY, Meulemeester MD, Rovensky J, Arulmani U, et al. Canakinumab reduces risk of acute gouty arthritis flares during initiation of allopurinol treatment: Results of a double blind, randomised study. Ann Rheum Disease 2011;70:1264-71.
13. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51:321-5. (Pubitemid 38725128)
14. Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids 2008;27:585-91. (Pubitemid 351948555)
15. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24. (Pubitemid 44620440)
16. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout (executive summary). Rheumatology 2007;46:1372-4.
17. Schlesinger N. Management of acute and chronic gouty arthritis: Present state-of-the-art. Drugs 2004;64:2399-416. (Pubitemid 39480701)
18. Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: Analysis of data from three phase III trials. Clin Ther 2010;32:2386-97.